Lainie Martin, MD
Basic profileAssociate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania · Hospital of the University of Pennsylvania
Lainie Martin is Associate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania at Hospital of the University of Pennsylvania. OpenAlex indexes 280 publications with 7,702 citations (h-index 41); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Updated 24 Oct 2026
Lainie Martin, M.D., is Associate Professor of Medicine (Hematology-Oncology), Hospital of the University of Pennsylvania at University of Pennsylvania Perelman School of Medicine / Hospital of the University of Pennsylvania (Penn Medicine). The public record shows 280 publications with 7,749 citations (h-index 41), centered on Ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, BRCA gene mutations in cancer. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 6 companies, 1 NIH-funded awards (2010–2014).
- Most recent indexed publication: 2025 · Journal of the National Cancer Institute
- Top research focus: Ovarian cancer diagnosis and treatment
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 74.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St
Philadelphia, PA 19104
Telephone
215-615-0063Registry record last updated 29 May 2018 · collected 28 Jul 2026.
Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Sponsor: Novartis Pharmaceuticals
Industry payments
Updated 24 Oct 2026
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
- Genmab U.S., Inc.Program year20246 payments$12,377openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
37.8%Serotonin-3 Receptor Antagonist37.8%Ondansetron Hcl100%Part D≥12 patientsBlood & clotting
32.4%Factor Xa inhibitor32.4%Eliquis100%Part D<11 patientsNervous system
29.7%Phenothiazine29.7%Prochlorperazine Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 24 Oct 2026
1 NIH research award on record, funded 2010–2014 per NIH RePORTER. The latest:
- Evaluation of In Vivo Optical Imaging in Pancreatic and Ovarian Cancer Patients
Research Inst of Fox Chase Can Ctr
FY2014$147,300R01CA151374
Congress activity
Updated 24 Oct 2026
46 congress contributions (2009–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer.
Journal of the National Cancer Institute
Article2025
Most-cited works
by citation count (OpenAlex)- 01Platinum Resistance: The Role of DNA Repair PathwaysArticle754 citations2008
- 02Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in OncologyArticle717 citations2021
- 03Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian CancerArticle505 citations2023
- 04NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022Article403 citations2022
- 05Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian CancerArticle368 citations2016
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
- Spent 15 years at Fox Chase Cancer Center
where she led the Gynecologic Research Program (past)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sutrobio.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Mohamed Gad, MD, MPH
Hospital of the University of Pennsylvania
Selina Luger, MD
Hospital of the University of Pennsylvania
Ian Frank, MD
Hospital of the University of Pennsylvania
Simin Goral, MD
Hospital of the University of Pennsylvania
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”